nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—MAOA—schizophrenia	0.23	0.298	CbGaD
Phenylpropanolamine—DRD1—schizophrenia	0.21	0.271	CbGaD
Phenylpropanolamine—SLC6A3—schizophrenia	0.199	0.257	CbGaD
Phenylpropanolamine—CYP1A2—schizophrenia	0.135	0.175	CbGaD
Phenylpropanolamine—SLC6A2—locus ceruleus—schizophrenia	0.00742	0.108	CbGeAlD
Phenylpropanolamine—MAOA—locus ceruleus—schizophrenia	0.00683	0.0997	CbGeAlD
Phenylpropanolamine—DRD1—telencephalic ventricle—schizophrenia	0.00542	0.0791	CbGeAlD
Phenylpropanolamine—SLC6A3—telencephalic ventricle—schizophrenia	0.00436	0.0636	CbGeAlD
Phenylpropanolamine—SLC6A2—autonomic nervous system—schizophrenia	0.00394	0.0575	CbGeAlD
Phenylpropanolamine—CYP1A2—urine—schizophrenia	0.00247	0.036	CbGeAlD
Phenylpropanolamine—MAOA—blood plasma—schizophrenia	0.00154	0.0225	CbGeAlD
Phenylpropanolamine—DRD1—forebrain—schizophrenia	0.00142	0.0207	CbGeAlD
Phenylpropanolamine—DRD1—telencephalon—schizophrenia	0.0013	0.019	CbGeAlD
Phenylpropanolamine—CYP1A2—blood plasma—schizophrenia	0.00129	0.0188	CbGeAlD
Phenylpropanolamine—ADRA2A—blood plasma—schizophrenia	0.00119	0.0173	CbGeAlD
Phenylpropanolamine—SLC6A3—forebrain—schizophrenia	0.00114	0.0166	CbGeAlD
Phenylpropanolamine—ADRB1—forebrain—schizophrenia	0.00108	0.0157	CbGeAlD
Phenylpropanolamine—SLC6A3—telencephalon—schizophrenia	0.00105	0.0153	CbGeAlD
Phenylpropanolamine—ADRB1—telencephalon—schizophrenia	0.000993	0.0145	CbGeAlD
Phenylpropanolamine—DRD1—midbrain—schizophrenia	0.000935	0.0136	CbGeAlD
Phenylpropanolamine—SLC6A2—forebrain—schizophrenia	0.000918	0.0134	CbGeAlD
Phenylpropanolamine—ADRA1A—forebrain—schizophrenia	0.000854	0.0125	CbGeAlD
Phenylpropanolamine—MAOA—forebrain—schizophrenia	0.000846	0.0123	CbGeAlD
Phenylpropanolamine—SLC6A2—telencephalon—schizophrenia	0.000845	0.0123	CbGeAlD
Phenylpropanolamine—ADRA1A—telencephalon—schizophrenia	0.000785	0.0115	CbGeAlD
Phenylpropanolamine—MAOA—telencephalon—schizophrenia	0.000778	0.0113	CbGeAlD
Phenylpropanolamine—DRD1—nervous system—schizophrenia	0.000769	0.0112	CbGeAlD
Phenylpropanolamine—SLC6A3—midbrain—schizophrenia	0.000752	0.011	CbGeAlD
Phenylpropanolamine—DRD1—central nervous system—schizophrenia	0.00074	0.0108	CbGeAlD
Phenylpropanolamine—SLC6A2—gonad—schizophrenia	0.000705	0.0103	CbGeAlD
Phenylpropanolamine—Ephedrine—SLC18A2—schizophrenia	0.000656	0.099	CrCbGaD
Phenylpropanolamine—ADRA2A—forebrain—schizophrenia	0.000649	0.00947	CbGeAlD
Phenylpropanolamine—ADRB1—endocrine gland—schizophrenia	0.000626	0.00913	CbGeAlD
Phenylpropanolamine—SLC6A3—nervous system—schizophrenia	0.000618	0.00901	CbGeAlD
Phenylpropanolamine—ADRA2A—telencephalon—schizophrenia	0.000597	0.00871	CbGeAlD
Phenylpropanolamine—SLC6A3—central nervous system—schizophrenia	0.000595	0.00868	CbGeAlD
Phenylpropanolamine—DRD1—brain—schizophrenia	0.000588	0.00857	CbGeAlD
Phenylpropanolamine—ADRB1—nervous system—schizophrenia	0.000586	0.00855	CbGeAlD
Phenylpropanolamine—SLC6A3—cerebellum—schizophrenia	0.000582	0.00848	CbGeAlD
Phenylpropanolamine—ADRA1A—blood—schizophrenia	0.000571	0.00833	CbGeAlD
Phenylpropanolamine—MAOA—blood—schizophrenia	0.000566	0.00825	CbGeAlD
Phenylpropanolamine—ADRB1—central nervous system—schizophrenia	0.000564	0.00823	CbGeAlD
Phenylpropanolamine—MAOA—midbrain—schizophrenia	0.000559	0.00815	CbGeAlD
Phenylpropanolamine—SLC6A2—endocrine gland—schizophrenia	0.000533	0.00777	CbGeAlD
Phenylpropanolamine—Dextroamphetamine—SLC18A2—schizophrenia	0.0005	0.0755	CrCbGaD
Phenylpropanolamine—SLC6A2—nervous system—schizophrenia	0.000499	0.00727	CbGeAlD
Phenylpropanolamine—ADRA2A—gonad—schizophrenia	0.000498	0.00727	CbGeAlD
Phenylpropanolamine—ADRA1A—endocrine gland—schizophrenia	0.000495	0.00722	CbGeAlD
Phenylpropanolamine—MAOA—endocrine gland—schizophrenia	0.000491	0.00716	CbGeAlD
Phenylpropanolamine—SLC6A2—central nervous system—schizophrenia	0.00048	0.007	CbGeAlD
Phenylpropanolamine—SLC6A3—brain—schizophrenia	0.000472	0.00689	CbGeAlD
Phenylpropanolamine—L-Phenylalanine—TH—schizophrenia	0.000472	0.0713	CrCbGaD
Phenylpropanolamine—CYP1A2—blood—schizophrenia	0.000472	0.00689	CbGeAlD
Phenylpropanolamine—ADRA1A—nervous system—schizophrenia	0.000464	0.00676	CbGeAlD
Phenylpropanolamine—MAOA—nervous system—schizophrenia	0.000459	0.0067	CbGeAlD
Phenylpropanolamine—ADRB1—brain—schizophrenia	0.000448	0.00654	CbGeAlD
Phenylpropanolamine—ADRA1A—central nervous system—schizophrenia	0.000446	0.00651	CbGeAlD
Phenylpropanolamine—MAOA—central nervous system—schizophrenia	0.000442	0.00645	CbGeAlD
Phenylpropanolamine—ADRA1A—cerebellum—schizophrenia	0.000436	0.00636	CbGeAlD
Phenylpropanolamine—ADRA2A—blood—schizophrenia	0.000434	0.00633	CbGeAlD
Phenylpropanolamine—MAOA—cerebellum—schizophrenia	0.000432	0.0063	CbGeAlD
Phenylpropanolamine—ADRA2A—midbrain—schizophrenia	0.000429	0.00625	CbGeAlD
Phenylpropanolamine—CYP1A2—endocrine gland—schizophrenia	0.00041	0.00597	CbGeAlD
Phenylpropanolamine—Amphetamine—SLC18A2—schizophrenia	0.000403	0.0609	CrCbGaD
Phenylpropanolamine—SLC6A2—brain—schizophrenia	0.000381	0.00556	CbGeAlD
Phenylpropanolamine—ADRA2A—endocrine gland—schizophrenia	0.000377	0.00549	CbGeAlD
Phenylpropanolamine—Methamphetamine—SLC18A2—schizophrenia	0.000374	0.0564	CrCbGaD
Phenylpropanolamine—ADRA1A—brain—schizophrenia	0.000354	0.00517	CbGeAlD
Phenylpropanolamine—ADRA2A—nervous system—schizophrenia	0.000352	0.00514	CbGeAlD
Phenylpropanolamine—MAOA—brain—schizophrenia	0.000351	0.00512	CbGeAlD
Phenylpropanolamine—ADRA2A—central nervous system—schizophrenia	0.000339	0.00495	CbGeAlD
Phenylpropanolamine—ADRA2A—cerebellum—schizophrenia	0.000332	0.00484	CbGeAlD
Phenylpropanolamine—Tranylcypromine—MAOA—schizophrenia	0.000301	0.0454	CrCbGaD
Phenylpropanolamine—ADRA2A—brain—schizophrenia	0.000269	0.00393	CbGeAlD
Phenylpropanolamine—Phentermine—MAOA—schizophrenia	0.000252	0.0381	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—MAOA—schizophrenia	0.000239	0.0361	CrCbGaD
Phenylpropanolamine—Phentermine—SLC6A3—schizophrenia	0.000218	0.0328	CrCbGaD
Phenylpropanolamine—Dextroamphetamine—SLC6A3—schizophrenia	0.000208	0.0313	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—SLC6A3—schizophrenia	0.000206	0.0311	CrCbGaD
Phenylpropanolamine—Phenelzine—MAOA—schizophrenia	0.000206	0.031	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—TNF—schizophrenia	0.000192	0.0289	CrCbGaD
Phenylpropanolamine—Methamphetamine—MAOA—schizophrenia	0.00018	0.0271	CrCbGaD
Phenylpropanolamine—Tranylcypromine—CYP1A2—schizophrenia	0.000177	0.0267	CrCbGaD
Phenylpropanolamine—Amphetamine—SLC6A3—schizophrenia	0.000167	0.0252	CrCbGaD
Phenylpropanolamine—Phentermine—SLC6A4—schizophrenia	0.000163	0.0245	CrCbGaD
Phenylpropanolamine—Methamphetamine—SLC6A3—schizophrenia	0.000155	0.0234	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—SLC6A4—schizophrenia	0.000154	0.0233	CrCbGaD
Phenylpropanolamine—Phentermine—CYP1A2—schizophrenia	0.000148	0.0224	CrCbGaD
Phenylpropanolamine—Benzyl alcohol—CYP1A2—schizophrenia	0.000143	0.0216	CrCbGaD
Phenylpropanolamine—Tranylcypromine—CYP2D6—schizophrenia	0.000136	0.0206	CrCbGaD
Phenylpropanolamine—Amphetamine—SLC6A4—schizophrenia	0.000125	0.0189	CrCbGaD
Phenylpropanolamine—Amphetamine—DRD2—schizophrenia	0.000124	0.0188	CrCbGaD
Phenylpropanolamine—Methamphetamine—SLC6A4—schizophrenia	0.000116	0.0175	CrCbGaD
Phenylpropanolamine—Phentermine—CYP2D6—schizophrenia	0.000114	0.0172	CrCbGaD
Phenylpropanolamine—Benzyl alcohol—CYP2D6—schizophrenia	0.00011	0.0166	CrCbGaD
Phenylpropanolamine—Dextroamphetamine—CYP2D6—schizophrenia	0.000109	0.0165	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—CYP2D6—schizophrenia	0.000108	0.0164	CrCbGaD
Phenylpropanolamine—Amphetamine—CYP2D6—schizophrenia	8.79e-05	0.0133	CrCbGaD
Phenylpropanolamine—Methamphetamine—CYP2D6—schizophrenia	8.15e-05	0.0123	CrCbGaD
Phenylpropanolamine—ADRA2A—Metabolism—CACNB2—schizophrenia	1.27e-05	8.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—FGA—schizophrenia	1.26e-05	8.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—HTR2A—schizophrenia	1.26e-05	8.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ATP2A2—schizophrenia	1.26e-05	8.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NPY—schizophrenia	1.26e-05	8.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NOTCH4—schizophrenia	1.26e-05	8.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HTR7—schizophrenia	1.26e-05	8.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—DRD2—schizophrenia	1.26e-05	8.34e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HTR2C—schizophrenia	1.26e-05	8.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—DPYD—schizophrenia	1.25e-05	8.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL3RA—schizophrenia	1.25e-05	8.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TLE3—schizophrenia	1.24e-05	8.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NPY—schizophrenia	1.23e-05	8.16e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ATP2A2—schizophrenia	1.23e-05	8.16e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NOTCH4—schizophrenia	1.23e-05	8.16e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NTRK2—schizophrenia	1.22e-05	8.1e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NDUFV2—schizophrenia	1.22e-05	8.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TLE1—schizophrenia	1.22e-05	8.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NRG3—schizophrenia	1.22e-05	8.08e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DRD3—schizophrenia	1.22e-05	8.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR1B—schizophrenia	1.21e-05	8.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—OXT—schizophrenia	1.21e-05	8.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GFAP—schizophrenia	1.2e-05	7.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GRM5—schizophrenia	1.19e-05	7.9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—OXT—schizophrenia	1.19e-05	7.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR1B—schizophrenia	1.19e-05	7.87e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DRD4—schizophrenia	1.18e-05	7.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCK—schizophrenia	1.17e-05	7.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HTR2A—schizophrenia	1.17e-05	7.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR1A—schizophrenia	1.17e-05	7.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CACNA1C—schizophrenia	1.16e-05	7.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TLE3—schizophrenia	1.15e-05	7.65e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—COMT—schizophrenia	1.15e-05	7.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NPS—schizophrenia	1.15e-05	7.63e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIP4K2A—schizophrenia	1.15e-05	7.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HTR2A—schizophrenia	1.15e-05	7.6e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—GSTP1—schizophrenia	1.15e-05	7.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR1A—schizophrenia	1.14e-05	7.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PDE4B—schizophrenia	1.14e-05	7.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3C2A—schizophrenia	1.13e-05	7.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD1—schizophrenia	1.13e-05	7.48e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR2C—schizophrenia	1.13e-05	7.48e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CNR1—schizophrenia	1.13e-05	7.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NPS—schizophrenia	1.13e-05	7.46e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCKAR—schizophrenia	1.12e-05	7.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR2C—schizophrenia	1.1e-05	7.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD1—schizophrenia	1.1e-05	7.32e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HTR7—schizophrenia	1.1e-05	7.29e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DRD2—schizophrenia	1.1e-05	7.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NTRK2—schizophrenia	1.1e-05	7.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD3—schizophrenia	1.09e-05	7.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ADORA2A—schizophrenia	1.09e-05	7.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCK—schizophrenia	1.09e-05	7.22e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ABCB1—schizophrenia	1.08e-05	7.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NTRK2—schizophrenia	1.07e-05	7.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PLA2G4A—schizophrenia	1.07e-05	7.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD3—schizophrenia	1.07e-05	7.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PDE4B—schizophrenia	1.06e-05	7.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD4—schizophrenia	1.06e-05	7.04e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—GSTM1—schizophrenia	1.05e-05	6.98e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PLA2G4A—schizophrenia	1.05e-05	6.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—FGA—schizophrenia	1.05e-05	6.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—HTR2A—schizophrenia	1.04e-05	6.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCKAR—schizophrenia	1.04e-05	6.92e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PRL—schizophrenia	1.04e-05	6.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD4—schizophrenia	1.04e-05	6.88e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP26B1—schizophrenia	1.04e-05	6.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NPY—schizophrenia	1.02e-05	6.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NOTCH4—schizophrenia	1.02e-05	6.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ATP2A2—schizophrenia	1.02e-05	6.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CYP2D6—schizophrenia	1.02e-05	6.73e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—SNAP25—schizophrenia	1.02e-05	6.73e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CNR1—schizophrenia	1.01e-05	6.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ADORA2A—schizophrenia	1.01e-05	6.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PLA2G4A—schizophrenia	9.96e-06	6.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CNR1—schizophrenia	9.92e-06	6.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD2—schizophrenia	9.89e-06	6.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR7—schizophrenia	9.89e-06	6.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR1B—schizophrenia	9.83e-06	6.51e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—OXT—schizophrenia	9.83e-06	6.51e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FGA—schizophrenia	9.71e-06	6.44e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—HTR2A—schizophrenia	9.71e-06	6.43e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—S100B—schizophrenia	9.68e-06	6.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR7—schizophrenia	9.67e-06	6.41e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD2—schizophrenia	9.67e-06	6.41e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—schizophrenia	9.54e-06	6.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HTR2A—schizophrenia	9.49e-06	6.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NPY—schizophrenia	9.46e-06	6.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NOTCH4—schizophrenia	9.46e-06	6.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ATP2A2—schizophrenia	9.46e-06	6.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR1A—schizophrenia	9.46e-06	6.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PRL—schizophrenia	9.34e-06	6.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NPS—schizophrenia	9.32e-06	6.17e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—MTHFR—schizophrenia	9.31e-06	6.17e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ERBB4—schizophrenia	9.26e-06	6.14e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GCLM—schizophrenia	9.25e-06	6.13e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TPH1—schizophrenia	9.25e-06	6.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CYP1A2—schizophrenia	9.18e-06	6.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PRL—schizophrenia	9.14e-06	6.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR2C—schizophrenia	9.14e-06	6.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD1—schizophrenia	9.14e-06	6.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—OXT—schizophrenia	9.13e-06	6.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR1B—schizophrenia	9.13e-06	6.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—TH—schizophrenia	9.05e-06	6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NTRK2—schizophrenia	8.89e-06	5.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD3—schizophrenia	8.85e-06	5.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HTR2A—schizophrenia	8.82e-06	5.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR1A—schizophrenia	8.79e-06	5.83e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—schizophrenia	8.72e-06	5.78e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PLA2G4A—schizophrenia	8.71e-06	5.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—S100B—schizophrenia	8.7e-06	5.77e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PRKD1—schizophrenia	8.7e-06	5.76e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—APOE—schizophrenia	8.67e-06	5.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NPS—schizophrenia	8.66e-06	5.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD4—schizophrenia	8.59e-06	5.69e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—APOA1—schizophrenia	8.57e-06	5.68e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NRG1—schizophrenia	8.55e-06	5.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—S100B—schizophrenia	8.52e-06	5.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR2C—schizophrenia	8.49e-06	5.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD1—schizophrenia	8.49e-06	5.63e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MEF2C—schizophrenia	8.47e-06	5.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ERBB4—schizophrenia	8.32e-06	5.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NTRK2—schizophrenia	8.26e-06	5.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD3—schizophrenia	8.22e-06	5.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CNR1—schizophrenia	8.2e-06	5.44e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—YWHAZ—schizophrenia	8.19e-06	5.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ERBB4—schizophrenia	8.14e-06	5.4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—EP300—schizophrenia	8.14e-06	5.39e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ERBB3—schizophrenia	8.01e-06	5.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD2—schizophrenia	8e-06	5.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR7—schizophrenia	8e-06	5.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD4—schizophrenia	7.98e-06	5.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PLA2G4A—schizophrenia	7.83e-06	5.19e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HTR2A—schizophrenia	7.71e-06	5.11e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—COMT—schizophrenia	7.69e-06	5.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NRG1—schizophrenia	7.68e-06	5.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GSTP1—schizophrenia	7.66e-06	5.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PLA2G4A—schizophrenia	7.66e-06	5.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—MAOA—schizophrenia	7.64e-06	5.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CNR1—schizophrenia	7.62e-06	5.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MEF2C—schizophrenia	7.61e-06	5.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PRL—schizophrenia	7.56e-06	5.01e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NRG1—schizophrenia	7.52e-06	4.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MEF2C—schizophrenia	7.45e-06	4.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR7—schizophrenia	7.44e-06	4.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD2—schizophrenia	7.44e-06	4.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—YWHAZ—schizophrenia	7.36e-06	4.88e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GAPDH—schizophrenia	7.26e-06	4.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ABCB1—schizophrenia	7.25e-06	4.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—YWHAZ—schizophrenia	7.2e-06	4.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ERBB3—schizophrenia	7.2e-06	4.77e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CLOCK—schizophrenia	7.19e-06	4.77e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—schizophrenia	7.18e-06	4.76e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—APOE—schizophrenia	7.16e-06	4.75e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—schizophrenia	7.09e-06	4.7e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—APOA1—schizophrenia	7.08e-06	4.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—S100B—schizophrenia	7.04e-06	4.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ERBB3—schizophrenia	7.04e-06	4.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PLA2G4A—schizophrenia	7.04e-06	4.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GSTM1—schizophrenia	7.04e-06	4.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PRL—schizophrenia	7.02e-06	4.65e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TPH2—schizophrenia	7.01e-06	4.65e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CACNB2—schizophrenia	7.01e-06	4.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR2A—schizophrenia	6.93e-06	4.59e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—DPYD—schizophrenia	6.9e-06	4.57e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ESR1—schizophrenia	6.84e-06	4.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR2A—schizophrenia	6.78e-06	4.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ERBB4—schizophrenia	6.74e-06	4.46e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—S100B—schizophrenia	6.54e-06	4.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APOE—schizophrenia	6.44e-06	4.27e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CACNA1C—schizophrenia	6.41e-06	4.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APOA1—schizophrenia	6.37e-06	4.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PLA2G4A—schizophrenia	6.33e-06	4.2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APOE—schizophrenia	6.3e-06	4.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ERBB4—schizophrenia	6.26e-06	4.15e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3C2A—schizophrenia	6.25e-06	4.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APOA1—schizophrenia	6.23e-06	4.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—MTHFR—schizophrenia	6.22e-06	4.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NRG1—schizophrenia	6.22e-06	4.12e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—GSK3B—schizophrenia	6.2e-06	4.11e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MEF2C—schizophrenia	6.16e-06	4.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ESR1—schizophrenia	6.15e-06	4.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ESR1—schizophrenia	6.01e-06	3.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—YWHAZ—schizophrenia	5.95e-06	3.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PLA2G4A—schizophrenia	5.88e-06	3.9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TP53—schizophrenia	5.82e-06	3.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ERBB3—schizophrenia	5.82e-06	3.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOE—schizophrenia	5.79e-06	3.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NRG1—schizophrenia	5.78e-06	3.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MEF2C—schizophrenia	5.72e-06	3.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOA1—schizophrenia	5.72e-06	3.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR2A—schizophrenia	5.6e-06	3.71e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SNAP25—schizophrenia	5.6e-06	3.71e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP2D6—schizophrenia	5.6e-06	3.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—GSK3B—schizophrenia	5.58e-06	3.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—YWHAZ—schizophrenia	5.53e-06	3.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—GSK3B—schizophrenia	5.46e-06	3.62e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ERBB3—schizophrenia	5.41e-06	3.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOE—schizophrenia	5.21e-06	3.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR2A—schizophrenia	5.21e-06	3.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOA1—schizophrenia	5.15e-06	3.41e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TH—schizophrenia	5e-06	3.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ESR1—schizophrenia	4.97e-06	3.3e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—EP300—schizophrenia	4.94e-06	3.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—AKT1—schizophrenia	4.92e-06	3.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOE—schizophrenia	4.84e-06	3.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOA1—schizophrenia	4.79e-06	3.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ESR1—schizophrenia	4.62e-06	3.06e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AKT1—schizophrenia	4.6e-06	3.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GSK3B—schizophrenia	4.51e-06	2.99e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—COMT—schizophrenia	4.25e-06	2.81e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTP1—schizophrenia	4.23e-06	2.8e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MAOA—schizophrenia	4.22e-06	2.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GSK3B—schizophrenia	4.19e-06	2.78e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AKT1—schizophrenia	4.18e-06	2.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AKT1—schizophrenia	4.13e-06	2.74e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—schizophrenia	4.09e-06	2.71e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EP300—schizophrenia	4.08e-06	2.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AKT1—schizophrenia	4.04e-06	2.68e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ABCB1—schizophrenia	4e-06	2.65e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PLA2G4A—schizophrenia	3.88e-06	2.57e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTM1—schizophrenia	3.88e-06	2.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AKT1—schizophrenia	3.75e-06	2.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AKT1—schizophrenia	3.67e-06	2.43e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EP300—schizophrenia	3.67e-06	2.43e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EP300—schizophrenia	3.59e-06	2.38e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MTHFR—schizophrenia	3.43e-06	2.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AKT1—schizophrenia	3.35e-06	2.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—EP300—schizophrenia	3.3e-06	2.19e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOE—schizophrenia	3.2e-06	2.12e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOA1—schizophrenia	3.16e-06	2.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AKT1—schizophrenia	3.11e-06	2.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AKT1—schizophrenia	3.04e-06	2.01e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AKT1—schizophrenia	2.98e-06	1.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EP300—schizophrenia	2.97e-06	1.97e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—schizophrenia	2.92e-06	1.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT1—schizophrenia	2.82e-06	1.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EP300—schizophrenia	2.76e-06	1.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—schizophrenia	2.63e-06	1.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—schizophrenia	2.57e-06	1.7e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT1—schizophrenia	2.47e-06	1.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT1—schizophrenia	2.22e-06	1.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT1—schizophrenia	2.17e-06	1.44e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—schizophrenia	2.13e-06	1.41e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AKT1—schizophrenia	1.99e-06	1.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—schizophrenia	1.97e-06	1.31e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—EP300—schizophrenia	1.82e-06	1.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT1—schizophrenia	1.79e-06	1.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT1—schizophrenia	1.67e-06	1.1e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKT1—schizophrenia	1.1e-06	7.29e-06	CbGpPWpGaD
